drugset / Trial / NCT02209649

Bioavailability of Lacidipine and Telmisartan Fixed Dose Combination Tablets Relative to Separate Tablets in Healthy Subjects

NCT02209649

Phase 1 Completed 12 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to compare the bioavailability of Lacidipine and Telmisartan administered as fixed dose combination tablets with the separate Telmisartan and Lacidipine tablets.

Timeline

Start
1999-10
Primary completion
1999-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lacidipine Small molecule 4 mg Oral
Comparator Telmisartan Other / unclassified 40 mg Oral

Indications

No indication recorded.